Pfizer Says COVID-19 Pill 90% Effective in Preventing Hospitalization & Death
Pfizer said its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients on Tuesday. Recent lab data has also confirmed that the drug is effective against the newly-fast-spreading Omicron variant.
The drugmaker said the drug was around 89% effective in preventing hospitalizations or deaths when compared to placebo last month, based on results in around 1,200 people. Data from its final analysis of the trial shared Tuesday, however, includes an additional 1,000 people. Nobody in the trial who received the Pfizer medicine died, as opposed to 12 among placebo receivers.
"It's a stunning outcome. We're talking about a staggering number of lives saved and hospitalizations prevented. And of course, if you deploy this quickly after infection, we are likely to reduce transmission dramatically“, Pfizer Chief Scientific Officer - Mikael Dolsten commented.
Pfizer also released early data from a second study, suggesting that the treatment reduced hospitalizations by around 70% in a smaller trial of standard-risk adults, including some higher-risk vaccinated people. While these results are still not statistically significant, and further trial results are expected in the near future.
Dolsten said he expects authorization for use in high-risk individuals from the US Food and Drug Administration and other regulatory agencies soon.
*The products advertised are only available to clients under Fondex Limited (SDL No: SD037). Trading CFDs involves significant risk of loss.